For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- MTPC Expects Fingolimod to Become Blockbuster: President Tsuchiya
December 13, 2010
- Cocokara fine Aims at Sales of ¥500 Bil. in FY2015
December 13, 2010
- Eisai Applies for SEP-190 for Insomnia
December 13, 2010
- Acotiamide to Drive Zeria's Global Business
December 13, 2010
- Early Price Settlement Unlikely: Mr Minari of Nihon Chouzai
December 13, 2010
- Kyowa Hakko Bio's Hofu Facility Complies with GMP Requirements: Korosho
December 13, 2010
- Teijin to Extend Pharma Business by Launching Feburic, Synvisc: Mr Ohyagi
December 13, 2010
- Qol to Open More Convenience Stores with Dispensing Services
December 13, 2010
- Ranbaxy Launches Generic Aricept in the US
December 13, 2010
- Blopress Returns to Top Place in 3rd Qtr: IMS Japan
December 13, 2010
- M3 Acquires EMS Research in the UK
December 13, 2010
- Hospira Japan Launches Its 1st In-house Oncology Generics
December 13, 2010
- Astellas Obtains Oncology Technology Platform from AVEO
December 13, 2010
- Itochu, PRISM BioLab to Market Library of Chemical Compounds
December 13, 2010
- Generics Should Be Priced at Lower Levels in Japan: Dr Eiki of Bayer Yakuhin
December 13, 2010
- Sawai to Re-Propose Merger to Kyorin
December 13, 2010
- Bayer, Regeneron to Apply for VEGF Trap-Eye in Europe, US in 2011
December 13, 2010
- Eisai to Donate Antifilarial Drug through WHO
December 13, 2010
- Global Players Accelerate Personnel Downsizing
December 13, 2010
- Takeda to Apply for Hematide in US in 2Q 2011
December 13, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…